Loading…
for educational and safety purposes
sci-wiki~$open stack serious-anhedonia
eight items for when nothing feels good, ordered by what has actually been tested against anhedonia rather than depression
8 items; 6 structures drawn from pubchem, 2 drawn generically because pubchem has no record of the name.
Anhedonia is the symptom antidepressants are worst at. It tracks reward circuitry rather than mood, it is what remains when a depression scale has otherwise improved, and it is the reason a lot of people describe treatment as working and not working at the same time.
This roster is the first in the set where the evidence check came back with good news. Pramipexole has a randomised placebo-controlled trial with anhedonia as the PRIMARY outcome, not a secondary one, and it separated from placebo with a moderate effect size while reward-related striatal activation held up. That is a genuinely different quality of evidence from anything else on this page, and it is why the order here is by evidence rather than by mechanism.
After that the gradient falls away fast. Vortioxetine has real but small anhedonia-specific numbers. Aticaprant was the most promising mechanism in the field and its phase 3 failed. The remaining five have no human anhedonia evidence at all, and two of them have no human evidence of any kind.
Pramipexole and vortioxetine are the pair with a rationale that survives contact with the literature: one works on the dopaminergic reward pathway where anhedonia actually lives, the other on the serotonergic system where most treatment already is. They are also the two prescription items, which is not a coincidence.
Memantine and agmatine both touch NMDA and are the most redundant pair here; the case for running both is weak.
Naltrexone belongs apart from the rest of this discussion rather than beside it. Blocking opioid receptors is the mechanism behind blunted pleasure response, and a stack aimed at restoring pleasure response containing an opioid antagonist deserves that stated plainly rather than assumed away.
Pramipexole is the item people notice, and not always pleasantly at first: nausea, dizziness and disturbed sleep were all more than twice as common as placebo in the trial, and titration is slow for that reason. What is reported when it works is not euphoria but the return of ordinary wanting.
Everything else here is either slow, unproven, or both.
PRAMIPEXOLE CARRIES A REAL IMPULSE-CONTROL RISK AND IT IS A CLASS EFFECT, NOT A RUMOUR. In 3,090 treated Parkinson's patients, 13.6 percent had an impulse control disorder; on a dopamine agonist it was 17.1 percent against 6.9 percent not on one, roughly a 2.7-fold odds increase, covering gambling, compulsive sexual behaviour, compulsive buying and binge eating. The anhedonia trial excluded people with existing impulse-control problems and found no gambling difference, but a quarter of the drug arm reported difficulty controlling buying at week three. Anyone starting this should tell someone close to them what to watch for. AND THE DOSES ARE NOT LOW. The anhedonia trial titrated to 4.5 mg and calls itself high-dose; the treatment-resistant depression trial reached 2.5 mg. Those are Parkinson's-range doses. The genuinely low-dose window for pramipexole is restless legs, which is a different literature. Sudden daytime sleepiness is a documented risk and matters for driving. 9-Me-BC HAS NO HUMAN EXPOSURE DATA AND A SPECIFIC CHEMICAL CONCERN. One further methylation produces 2,9-dimethyl-beta-carbolinium, a complex-I inhibitor that preferentially kills dopaminergic neurons in culture and depletes rat striatal dopamine, which its own authors compare to MPP+. There is no oral repeat-dose toxicology in any species. Pramipexole, vortioxetine, memantine and naltrexone are prescription medicines. Aticaprant and DNSP-11 are investigational and unavailable. Vortioxetine carries the antidepressant suicidality warning and interacts with anticoagulants and NSAIDs. Naltrexone precipitates withdrawal in anyone opioid-dependent and blocks opioid analgesia, which matters in an emergency. Anhedonia severe enough to search for this is a reason to see a psychiatrist, not a reason to assemble eight compounds.
8 pairs to notecurated roster
4 of 8 in one basketRUPharma
Aticaprant has no outlet here at all.
6 of 8 priced
2 of these carry no listed price, so there is no honest total to print; the lines above are what can actually be costed.
5 overlapssame lever, twice
interested in protocols? join the discord; that is where dosing, timing and the practical side get discussed.
the sci-wiki publishes this as a description of what these compounds do together, not as a recommendation to take them. Nothing here is medical advice.